2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2233 T-cell-redirecting therapies for relapsed/refractory multiple myeloma: A network meta-analysis

Ahmed Ali Khan, MD, Muhammad Uzair Sarfraz2, Muhammad Rehman Safdar, MD3, Muhammad Sameed Alam, MD4, Zuhair Abrar, MD5, Muhammad Ali Khan, MBBS6
1 Mayo Clinic, Phoenix, Arizona, United States
2 Tuscon Medical Center, Tuscon, Arizona, United States
3 King Edward Medical University, Lahore, Pakistan
4 King Edward Medical University, Lahore, Pakistan
5 Mayo Clinic, Phoenix, Arizona, United States
6 Mayo Clinic, Phoenix, Arizona, United States

Background: Relapsed/refractory multiple myeloma (RRMM) remains incurable, and the rapid expansion of BCMA- and GPRC5D-directed CAR T-cell and bispecific antibody (BsAb) therapies has created a major treatment-selection challenge. Their relative efficacy and safety remain uncertain because pivotal phase 3 trials used different standard-of-care (SOC) comparators, with almost no head-to-head evidence. We performed a network meta-analysis (NMA) of phase 3 randomized trials to compare these regimens and inform treatment selection.

Methods: MEDLINE, Embase, and CENTRAL were systematically searched from inception through July 31, 2026, for phase 3 randomized controlled trials (RCTs) of BCMA- or GPRC5D-directed CAR T-cell therapies or BsAbs in RRMM. BCMA-directed antibody–drug conjugates and trials reported only in press releases were excluded. Progression-free survival (PFS) and overall survival (OS) were analyzed as hazard ratios (HRs), whereas overall response rate (ORR), measurable residual disease (MRD) negativity at 10?5, and grade 3/4 adverse events (AEs) were analyzed as risk ratios (RRs) using intention-to-treat denominators. A frequentist fixed-effect NMA was performed, and treatments were ranked using P-scores. A prespecified MRD sensitivity analysis excluding KarMMa-3 assessed the robustness of treatment rankings to sparse control-arm events.

Results: Five phase 3 RCTs (2,849 randomized patients) were included. All effect estimates below compare each regimen with SOC. For PFS, teclistamab-daratumumab (tec-dara) ranked first (P-score, 0.99; HR [95% CI], 0.17 [0.12–0.24]), followed by talquetamab-daratumumab-pomalidomide (tal-dara-pom; 0.28 [0.20–0.40]), teclistamab monotherapy (tec-mono; 0.29 [0.23–0.37]), ciltacabtagene autoleucel (cilta-cel; 0.29 [0.22–0.39]), talquetamab-daratumumab (tal-dara; 0.33 [0.24–0.46]), and idecabtagene vicleucel (ide-cel; 0.49 [0.37–0.64]); all improved PFS. For OS, tec-dara ranked first (P-score, 0.80; HR [95% CI], 0.46 [0.32–0.66]), followed by tal-dara-pom (0.47 [0.30–0.73]), tal-dara (0.51 [0.33–0.78]), cilta-cel (0.55 [0.39–0.78]), and tec-mono (0.60 [0.43–0.83]); ide-cel did not improve OS (1.01 [0.73–1.40]). For ORR, ide-cel ranked first (P-score, 0.96; RR [95% CI], 1.71 [1.38–2.12]), followed by tec-mono (1.56 [1.39–1.75]), cilta-cel (1.26 [1.13–1.40]), tec-dara (1.18 [1.09–1.28]), tal-dara (1.14 [1.06–1.23]), and tal-dara-pom (1.14 [1.05–1.22]); all improved ORR. For MRD negativity, ide-cel ranked first (P-score, 0.98; RR [95% CI], 26.50 [3.70–189.64]), followed by tec-mono (5.45 [3.60–8.25]), cilta-cel (3.87 [2.78–5.40]), tec-dara (3.38 [2.54–4.51]), tal-dara-pom (3.29 [2.47–4.39]), and tal-dara (2.92 [2.18–3.92]). Ide-cel’s MRD estimate was unstable because of near-zero SOC events; after excluding KarMMa-3, tec-mono and cilta-cel were the two highest-ranked regimens. For grade 3/4 AEs, tal-dara ranked first for safety (P-score, 1.00) and reduced events versus SOC (RR, 0.82; 95% CI, 0.77–0.88). Tec-dara, tal-dara-pom, and cilta-cel did not differ significantly from SOC, whereas tec-mono (RR, 1.11; 95% CI, 1.03–1.21) and ide-cel (RR, 1.25; 95% CI, 1.12–1.39) increased grade 3/4 AEs.

Conclusions: For patients in whom maximal disease control is the priority, tec-dara may be favored based on its top PFS ranking and largest PFS benefit versus SOC. When minimizing severe toxicity is paramount, tal-dara may be favored as the only regimen that reduced grade 3/4 AEs versus SOC. ORR and MRD rankings should not guide selection in isolation, because ide-cel ranked highest despite less favorable PFS and OS and an unstable MRD estimate driven by sparse control-arm events. Because no significant OS differences were observed among the five non-ide-cel regimens and the shared SOC node represented different treatment lines and disease states, these findings support individualized selection based on prior target exposure, fitness, access, and toxicity profile rather than a universal treatment hierarchy.

Muhammad Uzair Sarfraz: No relevant conflicts of interest to declare.